Insider · CIK 0001564621
John B Moriarty
Files at MRTX (Mirati Therapeutics, Inc.), RNA (Avidity Biosciences, Inc.), KARD (Kardigan, Inc.). First filing Aug 5, 2025, latest Jan 9, 2026.
In brief
John B Moriarty files SEC Form 4 as officer at RNA (Avidity Biosciences, Inc.), and also at MRTX (Mirati Therapeutics, Inc.), KARD (Kardigan, Inc.). Since Aug 5, 2025, John B Moriarty has reported 0 open-market buys worth $0 and 2 open-market sells worth $253k, the latest filed on Jan 9, 2026.
A track record needs three past buys with six months of prices behind them; John B Moriarty has 0, so none is measured yet.
The newest scored trade: sold $171k of RNA on Jan 7, 2026, filed Jan 9, 2026, scored 21 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 1 sell worth $171k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
RNA: Avidity Biosciences, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 21Weak | Avidity Biosciences, Inc. | $171k 2,374 shares | -3% | - | |
| 19Weak | Avidity Biosciences, Inc. | $81k 2,245 shares | -4% | - |
Transactions
Every row this insider has filed, 13 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 17, 2026 | KARD Kardigan, Inc. | AGrant or award Common Stock | +47,784 | $0.00 | $0 | 47,784 | Jun 22, 2026 |
| Feb 27, 2026 | RNA Avidity Biosciences, Inc. | DDisposition to issuer Common Stock | -92,054 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | RNA Avidity Biosciences, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -50,000 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | RNA Avidity Biosciences, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -160,000 | - | - | 0 | Feb 27, 2026 |
| Jan 7, 2026 | RNA Avidity Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -2,374 | $72.23 | $171k | 74,557 | Jan 9, 2026 |
| Dec 17, 2025 | RNA Avidity Biosciences, Inc. | AGrant or award Common Stock | +56,000 | $0.00 | $0 | 103,755 | Dec 19, 2025 |
| Dec 17, 2025 | RNA Avidity Biosciences, Inc. | FTax withholding Common Stock | -26,824 | $71.87 | $1.9M | 76,931 | Dec 19, 2025 |
| Aug 4, 2025 | RNA Avidity Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -2,245 | $36.21 | $81k | 47,755 | Aug 5, 2025 |
| Jan 6, 2025 | RNA Avidity Biosciences, Inc. | AGrant or award Common Stock | +25,000 | $0.00 | $0 | 50,000 | Jan 8, 2025 |
| Jan 6, 2025 | RNA Avidity Biosciences, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Jan 8, 2025 |
| Jan 23, 2024 | MRTX Mirati Therapeutics, Inc. | DDisposition to issuer Common Stock | -675 | - | - | 71,660 | Jan 23, 2024 |
| Jan 23, 2024 | MRTX Mirati Therapeutics, Inc. | DDisposition to issuer Common Stock | -71,660 | - | - | 0 | Jan 23, 2024 |
| Jan 23, 2024 | MRTX Mirati Therapeutics, Inc. | DDisposition to issuer Option to Purchase Common Stockderivative | -83,525 | - | - | 0 | Jan 23, 2024 |
Questions about John B Moriarty
Answered from the filings on this page, as of the latest one.
Is John B Moriarty buying or selling?
In the last 12 months John B Moriarty reported 0 open-market buys worth $0 and 1 open-market sell worth $171k on SEC Form 4; the latest was sold $171k of RNA on Jan 7, 2026. Grants, option exercises and tax withholding are not counted.
How did John B Moriarty's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and John B Moriarty has 0.
Where does John B Moriarty file Form 4?
John B Moriarty has filed Form 4 at RNA (Avidity Biosciences, Inc.) as Chief Legal Officer; MRTX (Mirati Therapeutics, Inc.) as Chief Legal Officer; KARD (Kardigan, Inc.) as Chief Legal Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.